The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Abstract
PURPOSE: Two identical, concurrent, parallel, multicenter, randomized, double-blind, double-dummy trials were conducted to compare the efficacy and safety of zoledronic acid and pamidronate for treating hypercalcemia of malignancy (HCM). PATIENTS AND METHODS: Patients with moderate to severe HCM (corrected serum calcium [CSC] ≥ 3.00 mmol/L [12.0 mg/dL]) were treated with a single dose of zoledronic acid (4 or 8 mg) via 5-minute infusion or pamidronate (90 mg) via 2-hour infusion. A protocol-specified pooled analysis of the two parallel trials was performed. Clinical end points included rate of complete response by day 10, response duration, and time to relapse. RESULTS: Two hundred eighty-seven patients were randomized and evaluated for safety; 275 were evaluated for efficacy. Both doses of zoledronic acid were superior to pamidronate in the treatment of HCM. The complete response rates by day 10 were 88.4% (P = .002), 86.7% (P = .015), and 69.7% for zoledronic acid 4 mg and 8 mg and pamidronate 90 mg, respectively. Normalization of CSC occurred by day 4 in approximately 50% of patients treated with zoledronic acid and in only 33.3% of the pamidronate-treated patients. The median duration of complete response favored zoledronic acid 4 and 8 mg over pamidronate 90 mg with response durations of 32, 43, and 18 days, respectively. CONCLUSION: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Lipton, A., Theriault, R. L., Hortobagyi, G. N., Simeone, J., Knight, R. D., Mellars, K., Reitsma, D. J., Heffernan, M., & Seaman, J. J. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1082::aid-cncr20>3.0.co;2-z · Cited by 665
Self-citationBerenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Self-citationMundy, G. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1546::aid-cncr4>3.0.co;2-i · Cited by 440
Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
Green, J. R., Müller, K., & Jaeggi, K. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090521 · Cited by 415
The Hypercalcemia of Cancer: Clinical Implications and Pathogenic Mechanisms
Mundy, G. R., Ibbotson, K. J., D'Souza, S. M., Simpson, E. L., Jacobs, J. W., & Martin, T. J. (1984) · New England Journal of Medicine · doi:10.1056/nejm198406283102607 · Cited by 353
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
Aparicio, A., Gardner, A., Tu, Y., Savage, A., Berenson, J., & Lichtenstein, A. (1998) · Leukemia · doi:10.1038/sj.leu.2400892 · Cited by 259
Benford, H. L., Frith, J. C., Auriola, S., Mönkkönen, J., & Rogers, M. J. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26392-6 · Cited by 256
Bisphosphonates: Pharmacology, Mechanisms of Action and Clinical Uses
Russell, R. G. G., Croucher, P. I., & Rogers, M. J. (1999) · Osteoporosis International · doi:10.1007/pl00004164 · Cited by 240
Nussbaum, S. R., Younger, J., Vandepol, C. J., Gagel, R. F., Zubler, M. A., Chapman, R., Henderson, I. C., & Mallette, L. E. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90282-t · Cited by 228
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2009.01.009 · Cited by 1,328
Hypercalcemia Associated with Cancer
Stewart, A. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042806 · Cited by 973
Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral Density
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., Widmer, A., Devogelaer, J.-P., Kaufman, J.-M., Jaeger, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011807 · Cited by 877
Self-citationRosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., Coleman, R. E., Reitsma, D. J., et al. (2003) · Cancer · doi:10.1002/cncr.11701 · Cited by 873
Self-citation(2007) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2006.11.003 · Cited by 837
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Rosen, L. S., Gordon, D., Tchekmedyian, S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.105 · Cited by 729
Self-citationRosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Self-citationSMITH, M. R., EASTHAM, J., GLEASON, D. M., SHASHA, D., TCHEKMEDYIAN, S., & ZINNER, N. (2003) · Journal of Urology · doi:10.1097/01.ju.0000063820.94994.95 · Cited by 650
Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., & Takashima, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.116 · Cited by 546
Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.037 · Cited by 542
Ruggiero, S. L., Dodson, T. B., Assael, L. A., Landesberg, R., Marx, R. E., & Mehrotra, B. (2009) · Australian Endodontic Journal · doi:10.1111/j.1747-4477.2009.00213.x · Cited by 505
A systematic review of the role of bisphosphonates in metastatic disease
Ross, J., Saunders, Y., Edmonds, P., Patel, S., Wonderling, D., Normand, C., & Broadley, K. (2004) · Health Technology Assessment · doi:10.3310/hta8040 · Cited by 467
Durie, B. G. M., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., Anthony Child, J., Comenzo, R., Djulbegovic, B., Fantl, D., et al. (2003) · The Hematology Journal · doi:10.1038/sj.thj.6200312 · Cited by 427
Molecular mechanisms of novel therapeutic approaches for multiple myeloma
Hideshima, T., & Anderson, K. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc952 · Cited by 425
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Medical Applications and Toxicities of Gallium Compounds
Chitambar, C. R. (2010) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph7052337 · Cited by 380
Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases
Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., Goodin, S., LoRusso, P., Ma, P., Ravera, C., Deckert, F., et al. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491316 · Cited by 374
Self-citationNicolatou-Galitis, O., Schiødt, M., Mendes, R. A., Ripamonti, C., Hope, S., Drudge-Coates, L., Niepel, D., & Van den Wyngaert, T. (2019) · Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2018.09.008 · Cited by 361
Ruggiero, S. L., Gralow, J. R., Marx, R. E., Hoff, A. O., Schubert, M. M., Huryn, J. M., Toth, B., Damato, K., & Valero, V. (2006) · Journal of Oncology Practice · doi:10.1200/jop.2.1.7 · Cited by 355
Small, E. J., Smith, M. R., Seaman, J. J., Petrone, S., & Kowalski, M. O. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.147 · Cited by 341
Self-citationRosen, L. S., Gordon, D. H., Dugan, W., Major, P., Eisenberg, P. D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J., Chen, B., et al. (2004) · Cancer · doi:10.1002/cncr.11892 · Cited by 335
Self-citationMelani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z., & Colombo, M. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1882 · Cited by 329
Widler, L., Jaeggi, K. A., Glatt, M., Müller, K., Bachmann, R., Bisping, M., Born, A.-R., Cortesi, R., Guiglia, G., Jeker, H., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020819i · Cited by 315
Guidelines on the diagnosis and management of multiple myeloma 2005
Smith, A., Wisloff, F., Samson, D., & the UK Myeloma Forum, N. M. S. G. A. B. C. F. S. I. H. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05867.x · Cited by 311
Guidelines for the diagnosis and management of multiple myeloma 2011
Bird, J. M., Owen, R. G., D’Sa, S., Snowden, J. A., Pratt, G., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08573.x · Cited by 306
Hypercalcemia of malignancy: An update on pathogenesis and management
Mirrakhimov, A. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.170600 · Cited by 290
Bisphosphonates for the relief of pain secondary to bone metastases
Wong, R. K., & Wiffen, P. J. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002068 · Cited by 285
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Alsina, M., Atanackovic, D., Biermann, J. S., Chandler, J. C., Costello, C., Faiman, M., Fung, H. C., Gasparetto, C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0023 · Cited by 279
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L., Baljevic, M., Campagnaro, E., Castillo, J. J., Chandler, J. C., Costello, C., Efebera, Y., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0057 · Cited by 277
The diagnosis and management of hypercalcaemia
Minisola, S., Pepe, J., Piemonte, S., & Cipriani, C. (2015) · BMJ · doi:10.1136/bmj.h2723 · Cited by 275
Management of bone metastases in cancer: A review
Selvaggi, G., & Scagliotti, G. V. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.011 · Cited by 266
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Walker, M. D., & Shane, E. (2022) · JAMA · doi:10.1001/jama.2022.18331 · Cited by 260
Clines, G. A., & Guise, T. A. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00543 · Cited by 253
Symptom Management in Metastatic Breast Cancer
Irvin, W., Muss, H. B., & Mayer, D. K. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0159 · Cited by 112
Morony, S., Warmington, K., Adamu, S., Asuncion, F., Geng, Z., Grisanti, M., Tan, H. L., Capparelli, C., Starnes, C., Weimann, B., et al. (2005) · Endocrinology · doi:10.1210/en.2004-1583 · Cited by 97
Quinn, J. E., Brown, L. G., Zhang, J., Keller, E. T., Vessella, R. L., & Corey, E. (2005) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500815 · Cited by 29
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Metadata
- Authors
- Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., & Seaman, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-15
- Volume
- 19
- Issue
- 2
- Pages
- 558-567
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1951349736
- Cited by
- 858
- References
- 25
- FWCI
- 21.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.